Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Lymphoid 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 65Neoplasms 31Small Cell Lung Carcinoma 26Carcinoma, Hepatocellular 24Melanoma 23Colorectal Neoplasms 23Triple Negative Breast Neoplasms 20Carcinoma, Renal Cell 20Carcinoma, Transitional Cell 19Breast Neoplasms 18Neoplasm Metastasis 14Urinary Bladder Neoplasms 13Stomach Neoplasms 12Uterine Cervical Neoplasms 11Solid Tumors 11Squamous Cell Carcinoma of Head and Neck 10Ovarian Neoplasms 8Lymphoma 7Lung Neoplasms 7Lymphoma, Non-Hodgkin 6Head and Neck Neoplasms 6Esophageal Neoplasms 6Pancreatic Neoplasms 5Liver Neoplasms 5Carcinoma, Merkel Cell 5Advanced Solid Tumor 5Solid Tumor 4Prostatic Neoplasms 4Leukemia, Myeloid, Acute 4Kidney Neoplasms 4

Interventions

pembrolizumab 5atezolizumab 2Nivolumab 2fludarabine 1epacadostat 1durvalumab 1avelumab 1aldesleukin 1Interleukin-2 1Docetaxel 1Cyclophosphamide 1Carboxylesterase 1Bevacizumab 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Microsatellite Instability × atezolizumab × Clear all
NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

Phase 2 Active not recruiting
40 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡